Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The benefit of second-line chemotherapy (SL) after failed first-line chemotherapy (FL) in patients with advanced pancreatic cancer has not yet been established. We evaluated the clinical characteristics affecting the benefits of SL compared to best supportive care (BSC), identified the prognostic factors, and ultimately devised a model of clinical parameters to assist in making decision between SL and BSC after the failure of gemcitabine-based FL. Methods: The records of patients who received gemcitabine-based FL for advanced pancreatic cancer at Yonsei University Hospital between January 2010 and December 2015 were retrospectively reviewed. Significant clinical parameters were assessed for their potential as predictive factors. Results: SL patients received a longer duration of FL compared with BSC patients with median duration being 16.0 weeks (range, 8.0 to 26.0 weeks) and 8.0 weeks (range, 4.0 to 16.0 weeks), respectively (p<0.001). When the SL group was stratified by their modified overall survival (mOS) (longer and shorter than 6 months), we found significant differences for several clinical factors, namely, metastasis to the peritoneum (p<0.001), number of metastases (p<0.001), thrombotic events (p=0.003), and level of carbohydrate antigen 19-9 (CA19-9; p=0.011). In multivariate analysis, more than one site of metastasis, occurrence of thrombotic event during FL, and a CA19-9 level above 90 U/mL were significant independent prognostic factors for mOS in the SL group (p<0.05). When an attempt was made to devise a prognostic nomogram, Harrell’s C-index of the final prognosis prediction model was 0.62. Conclusions: SL may be beneficial for patients without peritoneal metastasis or thrombotic events who have a single metastasis and a level of CA19-9 less than 90 U/mL. This prognostic nomogram can be used to predict mOS before the administration of SL after the failure of gemcitabine-based FL.
Abstract
Background/Aims: The benefit of second-line chemotherapy (SL) after failed first-line chemotherapy (FL) in patients with advanced pancreatic cancer has not yet been established. We evaluated the clinical characteristics affecting the benefits of SL compared to best supportive care (BSC), identified the prognostic factors, and ultimately devised a model of clinical parameters to assist in making decision between SL and BSC after the failure of gemcitabine-based FL. Methods: The records of patients who received gemcitabine-based FL for advanced pancreatic cancer at Yonsei University Hospital between January 2010 and December 2015 were retrospectively reviewed. Significant clinical parameters were assessed for their potential as predictive factors. Results: SL patients received a longer duration of FL compared with BSC patients with median duration being 16.0 weeks (range, 8.0 to 26.0 weeks) and 8.0 weeks (range, 4.0 to 16.0 weeks), respectively (p<0.001). When the SL group was stratified by their modified overall survival (mOS) (longer and shorter than 6 months), we found significant differences for several clinical factors, namely, metastasis to the peritoneum (p<0.001), number of metastases (p<0.001), thrombotic events (p=0.003), and level of carbohydrate antigen 19-9 (CA19-9; p=0.011). In multivariate analysis, more than one site of metastasis, occurrence of thrombotic event during FL, and a CA19-9 level above 90 U/mL were significant independent prognostic factors for mOS in the SL group (p<0.05). When an attempt was made to devise a prognostic nomogram, Harrell’s C-index of the final prognosis prediction model was 0.62. Conclusions: SL may be beneficial for patients without peritoneal metastasis or thrombotic events who have a single metastasis and a level of CA19-9 less than 90 U/mL. This prognostic nomogram can be used to predict mOS before the administration of SL after the failure of gemcitabine-based FL.
참고문헌 (25)
- Oettle H, "Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer : outcomes from the CONKO-003 trial", J Clin Oncol, 32, pp.2423~2429 (2014)
- Rahma OE, "Second-line treatment in advanced pancreatic cancer : a comprehensive analysis of published clinical trials", Ann Oncol, 24, pp.1972~1979 (2013)
- Passero FC Jr, "Second line treatment options for pancreatic cancer", Expert Opin Pharmacother, 18, pp.1607~1617 (2017)
- Gill S, "PANCREOX : a randomized phase III study of fluorouracil", leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy, 2016, pp.34, 3914~3920
- Sarabi M, "Use of gemcitabine as a second-line treatment following chemotherapy with FOLFIRINOX for metastatic pancreatic adenocarcinoma", Oncol Lett, 13, pp.4917~4924 (2017)
- Rahman FAU, "Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer", Therap Adv Gastroenterol, 10, pp.563~572 (2017)
- Sinn M, "Second-Line treatment in pancreatic cancer patients : who profits? Results from the CONKO study group", Pancreas, 45, pp.601~605 (2016)
- Aprile G, "Second-line chemotherapy for advanced pancreatic cancer: which is the best option?", Crit Rev Oncol Hematol, 115, pp.1~12 (2017)
- Sonbol MB, "Second-line treatment in patients with pancreatic ductal adenocarcinoma : a meta-analysis", Cancer, 123, pp.4680~4686 (2017)
- Fiore M, "Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer", Sci Rep, 7, pp.45845~ (2017)
- Vernerey D, "Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer(PROLAP)", Br J Cancer, 115, pp.281~289 (2016)
- Kim ST, "A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy", Clin Oncol(R Coll Radiol), 24, pp.105~111 (2012)
- 청광현, "Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy", Gut and Liver, 11(2), pp.298~305 (2017), 거트앤리버 소화기연관학회협의회
- Custodio A, "Second-line therapy for advanced pancreatic cancer : a review of the literature and future directions", Cancer Treat Rev, 35, pp.676~684 (2009)
- Boeck S, "Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer", J Clin Oncol, 26, pp.1178~1179 (2008)
- Berger AK, "Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients(≥70 years of age) : a retrospective cohort study at the National Center for Tumor Diseases Heidelberg", Pancreatology, 14, pp.211~215 (2014)
- Maréchal R, "Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer", Oncology, 73, pp.41~51 (2007)
- Petrelli F, "Second line with oxaliplatin-or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer : a systematic review", Eur J Cancer, 81, pp.174~182 (2017)
- Fornaro L, "Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination : a multicenter survey and pooled analysis with published data", J Exp Clin Cancer Res, 34, pp.156~ (2015)
- Viaud J, "Gemcitabine as second-line chemotherapy after FOLFIRINOX failure in advanced pancreatic adenocarcinoma : a retrospective study", Dig Liver Dis, 49, pp.692~696 (2017)
- Ouyang H, "Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care", Pancreatology, 17, pp.773~781 (2017)
- Gharaibeh M, "Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer", J Med Econ, 20, pp.345~352 (2017)
- Kobayashi N, "Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure", Medicine(Baltimore), 96, pp.e6769~ (2017)
- Vienot A, "Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma", J Natl Cancer Inst, 109 (2017)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)